ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.848,77
-0,34%
S&P 500
6.037,59
1,06%
Dow Jones
43.325,80
0,07%
Euro vs US Dollar
1,04188
-0,03%
Bitcoin
95.669,12
-0,02%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Cartesian Therapeutics Inc (RNAC) Börsenkurse

Cartesian Therapeutics Inc

Cartesian Therapeutics Inc (RNAC)

NASDAQ
19,88
1,41
(7,63%)
Beim Schlusskurs: 27 Dezember 10:00PM
Verzögert um 15 Minuten
19,88
-0,04
( -0,20% )
Nach Börsenschluss: 11:37PM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
19,88
Gebot
16,70
Fragen
21,50
Volumen
39.754
18,27 Tagesbereich 19,97
11,665 52-Wochen-Bereich 41,87
Marktkapitalisierung
505,248M
Handelsende
18,47
Handelsbeginn
18,27
Letzte Trade
1
@
19.09
Letzter Handelszeitpunkt
22:30:49
Finanzvolumen
US$ 774.715
VWAP
19,4877
Durchschnittliches Volumen (3 Mio.)
132.033
Ausgegebene Aktien
25.414.898
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-2,30
Gewinn pro Aktie (EPS)
-8,64
Erlöse
26M
Nettogewinn
-219,71M

Über Cartesian Therapeutics Inc

Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL... Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.selectabio.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Cartesian Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RNAC. The last closing price for Cartesian Therapeutics was US$18,47. Over the last year, Cartesian Therapeutics shares have traded in a share price range of US$ 11,665 to US$ 41,87.

Cartesian Therapeutics currently has 25.414.898 shares in issue. The market capitalisation of Cartesian Therapeutics is US$469,41 million. Cartesian Therapeutics has a price to earnings ratio (PE ratio) of -2.30.

RNAC Neueste Nachrichten

Weitere Nachrichten

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the...

18 Dezember 2024
GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933

13 Dezember 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

13 Dezember 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

13 Dezember 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

11 Dezember 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

10 Dezember 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

09 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

03 Dezember 2024
Edgar (US Regulatory)

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3...

03 Dezember 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

22 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
11.799.8949695964618.0920.29516.727085919.06298915CS
41.699.2908191313918.1926.516.716599020.19206375CS
121.977411.045323025717.902626.515.513203320.28402562CS
26-4.03-16.854872438323.9129.6512.4813682618.39082175CS
52-2.17-9.8412698412722.0541.8711.66528218820.29685942CS
156-4.315-17.834263277524.19542.611.66537391022.70545953CS
260-4.315-17.834263277524.19542.611.66537391022.70545953CS

RNAC - Frequently Asked Questions (FAQ)

What is the current Cartesian Therapeutics share price?
The current share price of Cartesian Therapeutics is US$ 19,88
How many Cartesian Therapeutics shares are in issue?
Cartesian Therapeutics has 25.414.898 shares in issue
What is the market cap of Cartesian Therapeutics?
The market capitalisation of Cartesian Therapeutics is USD 469,41M
What is the 1 year trading range for Cartesian Therapeutics share price?
Cartesian Therapeutics has traded in the range of US$ 11,665 to US$ 41,87 during the past year
What is the PE ratio of Cartesian Therapeutics?
The price to earnings ratio of Cartesian Therapeutics is -2,3
What is the cash to sales ratio of Cartesian Therapeutics?
The cash to sales ratio of Cartesian Therapeutics is 19,47
What is the reporting currency for Cartesian Therapeutics?
Cartesian Therapeutics reports financial results in USD
What is the latest annual turnover for Cartesian Therapeutics?
The latest annual turnover of Cartesian Therapeutics is USD 26M
What is the latest annual profit for Cartesian Therapeutics?
The latest annual profit of Cartesian Therapeutics is USD -219,71M
What is the registered address of Cartesian Therapeutics?
The registered address for Cartesian Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Cartesian Therapeutics website address?
The website address for Cartesian Therapeutics is www.selectabio.com
Which industry sector does Cartesian Therapeutics operate in?
Cartesian Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
TOIIWOncology Institute Inc
US$ 0,0197
(109,57%)
42,81k
EVAXEvaxion Biotech AS
US$ 1,64
(93,85%)
7,03M
INTZIntrusion Inc
US$ 0,8011
(78,02%)
3,71M
KITTNauticus Robotics Inc
US$ 2,6799
(50,56%)
6,04M
RVSNRail Vision Ltd
US$ 1,15
(48,66%)
7,84M
MITAColiseum Acquisition Corporation
US$ 9,00
(-21,81%)
11,96k
BDRXBiodexa Pharmaceuticals PLC
US$ 4,04
(-14,04%)
4,42k
CTCXCarmell Corporation
US$ 0,285
(-11,49%)
163,45k
SPRCSciSparc Ltd
US$ 0,4464
(-10,72%)
2,09M
DOMHDominari Holdings Inc
US$ 1,11
(-10,48%)
3,06k
CRKNCrown Electrokinetics Corporation
US$ 0,16
(21,49%)
38,06M
OMEXOdyssey Marine Exploration Inc
US$ 0,61
(26,95%)
9,82M
QSIQuantum Si Inc
US$ 2,63
(22,33%)
9,26M
XTIAXTI Aerospace Inc
US$ 0,03995
(-0,13%)
8,28M
RVSNRail Vision Ltd
US$ 1,15
(48,66%)
7,84M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
RNAC
Cartesian Therapeutics
TSXV
RHC.WT.A
Royal Helium
BIT
UTIW
Amundi S&P Global Utilit...
TSXV
AGMR.WT.A
Silver Mountain Resources
DBI
I2RT
IN XTK MSCI WLDCLITRDL
TSX
PAAS
Pan American Silver
NASDAQ
AMAOU
American Acquisition Opp...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten